This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
PARK7 / Parkinson disease protein 7 · IHC design guide
Design Immunohistochemistry for PARK7
Plan PARK7 staining in paraffin sections using cytoplasmic and nuclear tissue staining as the expected pattern (HPA tissue IHC). Compare cases with consistent fixation and include a positive tissue control, such as pancreas with high exocrine glandular cell staining (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
PARK7 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic and nuclear staining in most tissues (HPA tissue IHC) | |
| Staining pattern | Most tissues show cytoplasmic and nuclear cell staining (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet M00757-4) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | None in HPA (detected in all 44 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image M00757-4) | |
| Caveat | Oxidative stress can shift PARK7 toward mitochondria and nucleus (UniProt) | |
| Regulation | No expression induction is specified (UniProt) | |
| Isoform / epitope | No isoforms or signal peptide are annotated; epitope is unspecified (UniProt) |
Section 1
Recommended PARK7 IHC & IF Protocols
The catalog antibody’s IHC-P protocol (datasheet M00757-4) is accompanied by three published PARK7 IHC protocols (PMC6377712; PMC3260266; PMC11538469).
| Sample | Paraffin-embedded human endometrial carcinoma tissue; fixative not specified (datasheet M00757-4) |
| Fixation | Image fixative and duration unreported (datasheet M00757-4); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet M00757-4); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet M00757-4) |
| Primary antibody | Mouse monoclonal (clone 4B10) anti-PARK7, 2-5 µg/ml (datasheet M00757-4) |
| Primary incubation | Overnight at 4 °C (datasheet M00757-4) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet M00757-4) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | PARK7-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic and nuclear expression in most tissues. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA pH 8.0 retrieval (datasheet M00757-4); the adipose tissue protocol also used boiling EDTA pH 8 (PMC3260266).
Section 2
What Is the Expected PARK7 Staining Pattern?
PARK7 staining is expected mainly in the cytoplasm, with nuclear staining in many tissues (HPA: tissue IHC profile; UniProt Q99497: predominantly cytoplasmic under normal conditions). Assess the named cell population within each tissue: HPA reports High staining in several glandular and other cell types, and Low staining in others (HPA: tissue IHC). The tissue IHC profile has Supported reliability, with medium consistency between staining and RNA data (HPA: tissue IHC reliability). PARK7 has no transmembrane segment (UniProt Q99497: topology).
| Cytoplasmic staining, with some nuclear staining, appears in glandular cells or other documented positive cells. | This fits the broad tissue pattern (HPA: cytoplasmic and nuclear expression in most tissues). For a stronger reference, examine an HPA High population such as pancreatic exocrine glandular cells or hippocampal glial cells (HPA: tissue IHC). Compare intensity within the identified cell population, because HPA assigns levels to cells within tissues. |
| Staining appears exclusively at cell borders or in an unexpected isolated compartment, without the expected cytoplasmic signal. | Treat this as a localization discrepancy to investigate, rather than a PARK7 positive result: the routine pattern is mainly cytoplasmic with some nuclear staining (UniProt Q99497: subcellular location; HPA: tissue IHC profile). UniProt lists additional locations, including mitochondria and membrane rafts, but those annotations alone do not validate a dominant cell-border pattern in a particular paraffin section (UniProt Q99497: subcellular location). |
| Strong staining appears chiefly in a cell population reported as Low, while documented High cells show little signal. | Check cell identification and assay specificity. Examples of Low populations include cardiomyocytes and vaginal squamous epithelial cells (HPA: tissue IHC). Unexpected chromogen can also reflect cross-reactivity or endogenous detection activity (general IHC practice). Low is a relative HPA category, not a requirement for complete absence of stain (HPA: tissue IHC levels). |
| Pale, widespread color obscures cell boundaries or appears over tissue and empty slide areas. | Interpret this as background until the staining run is checked (general IHC practice). Compare the negative reagent control, blocking, washes and chromogen development (general IHC practice). A true PARK7 pattern should remain interpretable by cell and compartment: cytoplasmic and nuclear expression is reported across most tissues (HPA: tissue IHC profile). |
| A documented High cell population is unstained. | Consider an unsuccessful staining run or antibody conditions before concluding biological absence (general IHC practice). Repeat alongside a documented positive population, such as breast glandular cells or lung alveolar type I cells (HPA: High tissue IHC). HPA reports no negative reference population in this payload; an unstained section therefore cannot by itself establish a valid PARK7 negative pattern (HPA: tissue IHC list). |
💡Expected PARK7 appearanceCall a section positive when the identified HPA High cell population shows clear, predominantly cytoplasmic staining with possible nuclear staining; isolated border staining or color outside cells is a suspect positive (HPA: tissue IHC profile and levels; UniProt Q99497: subcellular location; general IHC practice).
| Tissue and cell selection | Choose a named High population for a positive reference, such as duodenal glands of Brunner or pancreatic exocrine glandular cells (HPA: tissue IHC). Do not treat an entire organ as uniformly high: HPA levels refer to specified cells, and UniProt also reports higher expression in pancreatic islets than surrounding exocrine tissue (UniProt Q99497: tissue specificity). |
| Antibody validation | HPA lists Supported IHC staining for HPA004190 and CAB005870 (HPA: antibody validation). This supports use of their observed tissue patterns as context, while the tissue profile itself has medium consistency with RNA data (HPA: tissue IHC reliability). Validation of those antibodies does not establish the specificity of a different catalog antibody. |
| Localization and biological state | Under normal conditions PARK7 is predominantly cytoplasmic, with lesser nuclear and mitochondrial localization (UniProt Q99497: subcellular location). Oxidative stress can drive mitochondrial and subsequent nuclear translocation (UniProt Q99497: subcellular location, PubMed:18711745); compartment shifts therefore need sample context and cannot be inferred from chromogen intensity alone. |
| IF/ICC Q: What pattern should an IF image show? | A: HPA reports nucleoplasm and cytosol as Supported main locations; flagellar centriole and mid piece are additional Approved locations (HPA: subcellular ICC-IF). HPA004190 has Supported ICC validation (HPA: antibodies). These IF observations guide localization comparison; they are not an IHC-P protocol or a guarantee of identical appearance in paraffin sections. |
| Situation | Likely cause | Next action |
|---|---|---|
| No signal in a documented High reference population. | The staining run, antibody dilution or retrieval conditions may need checking (general IHC practice); target-specific fixation sensitivity is unreported in the supplied sources. | Run a known High cell population alongside the sample and review the catalog antibody's IHC-P instructions, including its stated retrieval and dilution, before changing conditions (HPA: tissue IHC levels; general IHC practice). |
| The section has broad haze or deposit that masks compartments. | Excess background may come from blocking, washing or chromogen development conditions (general IHC practice). | Review the negative reagent control; optimize blocking and washes, and shorten development if the control also colors (general IHC practice). Score PARK7 only where cell boundaries and localization remain clear (HPA: tissue IHC profile). |
| Color persists in the negative reagent control. | Endogenous enzyme activity or nonspecific detection reagents can produce chromogen independently of the primary antibody (general IHC practice). | Check the detection chemistry and apply the corresponding endogenous activity control or quench, then repeat the negative reagent control (general IHC practice). |
| Signal is predominantly membranous, with little cytoplasmic staining. | The pattern conflicts with the usual predominant cytoplasmic location (UniProt Q99497: subcellular location); a border artifact or nonspecific stain is possible (general IHC practice). | Compare adjacent cells and the negative reagent control, then verify the pattern with an independently validated IHC antibody if available (general IHC practice; HPA: HPA004190 and CAB005870 IHC Supported). |
| A low-staining cell type looks brighter than the chosen High reference. | Cell identification, cross-reactivity or endogenous detection activity may explain the mismatch (general IHC practice); HPA categories are cell specific (HPA: tissue IHC). | Recheck tissue morphology and controls, then compare like cell populations rather than whole sections (general IHC practice; HPA: tissue IHC levels). |
| Nuclear staining is stronger than expected. | Nuclear PARK7 is documented, and oxidative stress can alter localization (HPA: tissue IHC profile; UniProt Q99497: subcellular location, PubMed:18711745). The image alone does not establish the cause. | Record cytoplasmic and nuclear staining separately, confirm the cell identity and assay controls, and interpret any proposed stress association against independent sample information (HPA: tissue IHC profile; general IHC practice). |
Experiment evidence
IHC & IF images showing PARK7 staining
M00757-4 · IHCIHC analysis of PARK7/DJ1 using anti-PARK7/DJ1 antibody (M00757-4). PARK7/DJ1 was detected in a paraffin-embedded section of human endometri
M00757-4 · IHCIHC analysis of PARK7/DJ1 using anti-PARK7/DJ1 antibody (M00757-4). PARK7/DJ1 was detected in a paraffin-embedded section of human esophagea
M00757-4 · IFIF analysis of PARK7/DJ1 using anti-PARK7/DJ1 antibody (M00757-4). PARK7/DJ1 was detected in an immunocytochemical section of Hela cells. En
PB9308 · IHCAnti-PARK7 vendor antibody, PB9308, IHC(P) IHC(P): Mouse Pancreas Tissue
PB9308 · IHCAnti-PARK7 vendor antibody, PB9308, IHC(P) IHC(P): Rat Pancreas Tissue
PB9308 · IFIF analysis of PARK7 using anti-PARK7 antibody (PB9308). PARK7 was detected in an immunocytochemical section of SK-OV-3 cells. Enzyme antige
M00757 · IHCImmunohistochemical analysis of paraffin-embedded human bladder cancer, using PARK7 Antibody.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000116288-PARK7/tissue/cerebral+cortex#imid_1572468
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000116288-PARK7/tissue/colon#imid_1572410
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000116288-PARK7/tissue/liver#imid_1572403
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000116288-PARK7/tissue/kidney#imid_1572396
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA004190; green = PARK7, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA004190; green = PARK7, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for PARK7 IHC & IF
🧪Run adrenal gland first and expect glandular cells to stain (HPA: High in adrenal gland glandular cells). HPA detects PARK7 in all 44 scored tissues, so there is no supported negative tissue; use no-primary and isotype controls, and do not assume that any cell population on the positive slide is internally negative (HPA: no negative tissue rows; PARK7 detected in all 44 scored tissues).
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: None in HPA: PARK7 is detected in all 44 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show PARK7 in A-431, U-251MG, U2OS, Sperm, with annotated localisation: Nucleoplasm (supported), Cytosol (supported) (HPA subcellular).
Technical controls: Include a secondary-only slide and a concentration-matched mouse IgG isotype control for the mouse catalog antibody, then confirm specificity with PARK7 knockout material where available (selected-SKU caption: mouse primary and anti-mouse secondary). For adrenal gland chromogenic IHC, quench endogenous peroxidase and compare any pigment with the secondary-only slide (selected-SKU caption: HRP/DAB detection; HPA: adrenal gland positive tissue).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported, and the selected-SKU paraffin-section caption does not state a fixative (selected-SKU tissue-IHC caption: fixative unreported). The reported IHC procedure uses heat retrieval in EDTA at pH 8.0; whether retrieval is required under other conditions is unreported (selected-SKU tissue-IHC caption). HPA has ICC-IF images, but the supplied evidence does not establish that IF or frozen sections are easier than paraffin IHC; adrenal pigment may complicate DAB interpretation (HPA: ICC-IF images; selected-SKU caption: DAB).
HPA tissue IHC evidence for PARK7
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
| Duodenum | Glands of Brunner | High | Protein (IHC) | HPA → |
| Epididymis | Glandular cells | High | Protein (IHC) | HPA → |
| Fallopian tube | Glandular cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: PARK7 is detected in all 44 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced PARK7 IHC Tips
Troubleshoot PARK7 staining in paraffin sections by checking retrieval, tissue handling, compartment patterns, controls and scoring before interpreting biological differences.
What retrieval conditions should I start with for PARK7 chromogenic IHC?
Start with heat-mediated antigen retrieval in EDTA at pH 8.0 for paraffin sections stained with M00757-4 (datasheet M00757-4). The caption documents this retrieval with 2 μg/ml primary antibody incubated overnight at 4°C, but does not state a heating time (datasheet M00757-4). Keep section thickness, heating duration and detection conditions constant while comparing retrieval runs (standard IHC practice). If staining is weak, adjust heating duration on matched sections before changing buffer conditions, and check whether tissue morphology remains intact (standard IHC practice). Judge improvement against the expected cytoplasmic and nuclear pattern rather than signal intensity alone (HPA tissue IHC: cytoplasmic and nuclear expression in most tissues).
How can I troubleshoot fixation when PARK7 staining is weak or uneven?
The M00757-4 tissue caption identifies a paraffin section but does not report its fixative, so target-specific fixation sensitivity is unknown (datasheet M00757-4). Record fixation method and duration for each specimen, and compare sections processed through the same workflow before assigning a staining difference to PARK7 biology (standard IHC practice). If staining varies across a block, inspect morphology and compare central and peripheral regions because tissue processing can produce uneven staining (standard IHC practice). Recheck retrieval and antibody incubation on a matched control section before changing fixation conditions for future specimens (standard IHC practice). Do not infer fixation tolerance from tissue expression patterns or PARK7 sequence annotations (HPA tissue IHC; UniProt Q99497).
Which cellular compartments should show convincing PARK7 staining?
Expect chiefly cytoplasmic staining with possible nuclear signal in tissue sections; HPA reports cytoplasmic and nuclear expression in most tissues (HPA tissue IHC). PARK7 is predominantly cytoplasmic under normal conditions, with lesser nuclear and mitochondrial localisation, while oxidative stress can shift it toward mitochondria and then the nucleus (UniProt Q99497). Assess compartment patterns within intact cells against a matched control and the section’s morphology, rather than treating every brown deposit as intracellular signal (standard IHC practice). A strong, exclusively surface-restricted pattern warrants investigation because PARK7 has no transmembrane segment (UniProt Q99497 topology). Compartment shifts alone cannot establish oxidative stress without independent context or markers (UniProt Q99497; standard IHC practice).
Could epitope accessibility or PARK7 modification explain discordant staining?
The supplied PARK7 record lists 0 isoforms and no transmembrane segment, but it does not specify the M00757-4 binding epitope (UniProt Q99497; datasheet M00757-4). PARK7 has annotated modifications including cysteine oxidation at residue 106, so modification-dependent recognition remains a possibility that this caption cannot resolve (UniProt Q99497; datasheet M00757-4). Compare matched sections across a controlled retrieval series and assess whether signal retains the expected cytoplasmic and nuclear distribution (HPA tissue IHC; standard IHC practice). If discordance persists, use an independently validated antibody with a known epitope or another orthogonal readout to test the pattern (standard IHC practice). Do not assign an epitope or isoform from staining alone (standard IHC practice).
How should I adapt PARK7 localisation checks to multiplex IF?
For IF/ICC, combine PARK7 with a marker of the cell population under study and inspect signal within individual cells; HPA reports supported nucleoplasmic and cytosolic localisation (HPA subcellular). Choose fluorophores in channels with low specimen autofluorescence, then inspect single-channel images and no-primary controls before interpreting overlap (standard IF practice). PARK7 lacks a transmembrane segment and is predominantly intracellular, so permeabilisation should give antibody access to cytosolic and nuclear epitopes, subject to the antibody’s unknown binding site (UniProt Q99497 topology and localisation; standard IF practice). Optimise permeabilisation on matched specimens because excessive treatment can damage morphology or redistribute soluble signal (standard IF practice). Keep these IF settings separate from the M00757-4 paraffin-section workflow (datasheet M00757-4).
How can I separate PARK7 signal from chromogenic background?
The M00757-4 caption used 10% goat serum blocking, 2 μg/ml primary antibody overnight at 4°C, a peroxidase-conjugated secondary, and DAB detection (datasheet M00757-4). Start troubleshooting with a no-primary control, an appropriate peroxidase block and careful washing so endogenous enzyme activity and nonspecific deposits are visible (standard IHC practice). Compare signal after modest primary-antibody or development-time adjustments while keeping retrieval and section processing matched (standard IHC practice). Treat diffuse precipitate, staining outside intact cells or signal concentrated at damaged edges cautiously rather than calling it PARK7 (standard IHC practice). Confirm that retained staining follows the expected cytoplasmic and nuclear distribution (HPA tissue IHC).
What scoring method best captures PARK7 expression and localisation? ⚠ ANSWER MARKED FOR VERIFICATION
Score intact cells by compartment, recording cytoplasmic and nuclear staining separately because both occur across many tissues (HPA tissue IHC). An H-score combines the percentage of cells at each intensity level with that level’s score; alternatively report % positive cells using a preset threshold (standard IHC practice). For spatial comparisons, report positive-cell density per mm² of viable tissue and normalise counts to the corresponding viable area (standard IHC practice). Keep retrieval, antibody concentration, DAB development and image-analysis thresholds consistent across the comparison set (standard IHC practice). Report the analysed cell population and exclude necrosis, folds and tissue edges from scoring (standard IHC practice).
When is an unusual PARK7 staining pattern likely to be artefactual?
A credible result shows staining within intact cells in compartments consistent with chiefly cytoplasmic and sometimes nuclear PARK7, with cell identity checked against morphology (HPA tissue IHC; UniProt Q99497). A solely surface-restricted pattern is questionable because PARK7 has no transmembrane segment, although membrane-associated localisation is annotated (UniProt Q99497 topology and localisation). Check unexpected positive cells against the relevant tissue context; HPA reports high staining in hippocampal glial cells and pancreatic exocrine glandular cells (HPA tissue IHC). Discount edge-concentrated deposits, necrotic regions and signal persisting in a no-primary control; check peroxidase blocking when endogenous enzyme activity is suspected (standard IHC practice). HPA rates tissue staining as Supported with medium agreement with RNA expression, so corroborate surprising biological claims independently (HPA tissue IHC).
Boster reagents
Best PARK7 / Parkinson disease protein 7 IHC Antibodies
Validated anti-PARK7 antibodies have paraffin-section IHC images from human carcinomas and mouse and rat pancreas, plus IF/ICC images from HeLa and SK-OV-3 cells (catalog IHC/IF captions).
Real IHC data
Anti-PARK7/DJ1 Antibody ® (monoclonal, 4B10)
Cat # M00757-4
Real IHC data
Anti-PARK7/DJ1 Antibody ®
Cat # PB9308
Real IHC data
Anti-PARK7/Dj 1 Rabbit Monoclonal Antibody
Cat # M00757
M00757-4 shows paraffin-section IHC in human endometrial carcinoma and IF/ICC in HeLa cells; M00757 shows paraffin-section IHC in human bladder cancer (respective image captions). PB9308 shows IHC in mouse and rat pancreas and human pancreatic cancer, plus IF/ICC in SK-OV-3 cells (PB9308 image captions).
Which to pick: For human tissue IHC, choose mouse monoclonal M00757-4 when its documented paraffin-section workflow is useful: its caption reports EDTA pH 8 retrieval and 2 μg/ml primary antibody (catalog host/clone; M00757-4 IHC caption). For IF/ICC, M00757-4 and rabbit PB9308 each have a cell image and list 5 μg/ml; M00757 lists IF/ICC but has no IF image in the payload (catalog applications, IF dilutions and image captions). For cross-species tissue IHC, PB9308 lists human, mouse and rat reactivity and has an IHC image for each; the fixative is unreported in all three SKUs’ IHC captions (catalog reactivity; respective IHC captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q99497 (PARK7_HUMAN, Parkinson disease protein 7).
- Human Protein Atlas. PARK7 tissue IHC expression (reliability: Supported).
- Human Protein Atlas. PARK7 subcellular location (ICC-IF): Mainly localized to the nucleoplasm and cytosol. In addition localized to the flagellar centriole and mid piece..
- Human Protein Atlas. PARK7 antibody validation summary (2 antibodies).
- Identification of differentially expressed proteins in the injured lung from zinc chloride smoke inhalation based on proteomics analysis. Respiratory research 2019 — PMC6377712.
- Uncovering suitable reference proteins for expression studies in human adipose tissue with relevance to obesity. PloS one 2012 — PMC3260266.
- Evaluation of expression profiles of APOA4, CEACAM1, CD147, DJ-1/PARK7, Gamma-synuclein, S100A1, and Stathmin-1 in urothelial carcinomas using immunohistochemical assays. Frontiers in oncology 2025 — PMC12678078.
- STUB1 suppresses paclitaxel resistance in ovarian cancer through mediating HOXB3 ubiquitination to inhibit PARK7 expression. Communications biology 2024 — PMC11538469.
- PubMed PMID:9070310 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
- PubMed PMID:16710414 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for PARK7 (Parkinson disease protein 7). Expected localisation Cytoplasmic and nuclear staining in most tissues (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet M00757-4). Validated IHC antibody: M00757-4 at 2-5 µg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative None in HPA (detected in all 44 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human endometrial carcinoma tissue; fixative not specified (datasheet M00757-4); 2. Fixation: Image fixative and duration unreported (datasheet M00757-4); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet M00757-4); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet M00757-4); 8. Primary antibody: Mouse monoclonal (clone 4B10) anti-PARK7, 2-5 µg/ml (datasheet M00757-4); 9. Primary incubation: Overnight at 4 °C (datasheet M00757-4). Watch for: Fixation: Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image M00757-4); Caveat: Oxidative stress can shift PARK7 toward mitochondria and nucleus (UniProt); Isoform / epitope: No isoforms or signal peptide are annotated; epitope is unspecified (UniProt); Regulation: No expression induction is specified (UniProt). Evidence: UniProt Q99497, HPA tissue IHC · Supported, HPA ICC-IF · Mainly localized to the nucleoplasm and cytosol. In addition…, Datasheet M00757-4, PMC6377712, PMC3260266. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/PARK7/immunohistochemistry-ihc-guide.